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Conclusions: CT guided high dose brachytherapy can be 
successfully implemented in a cancer centre achieving good 
levels of local control and overall survival. Node positivity on 
original MRI is predictive for recurrence.A complete response 
on week 5 MRI predicts for excellent long term pelvic control. 
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Purpose/Objective: To assess self-reported quality of life 
(QoL) experienced by cervical and endometrial cancer 
patients after radiation therapy and in regular follow up. Our 
purpose is to evaluate QoL related to urinary and bowel 
symptoms and sexual functioning in order to identify patient- 
and disease-related influencing factors. 
Materials and Methods: Since March 2011, 48 patients in 
regular follow-up for cervical cancer staged Ib1-IIIB (26 
operated and 22 non -operated) and to 82 patients in follow 
up for endometrial cancer staged IA-IIIC (76 operated and 6 
non -operated) after postoperative or radical pelvic 
radiotherapy ± brachytherapy boost were invited to fill in the 
anonymous EORTC-QLQ30 questionnaire. This questionnaire 
was combined with EN24 in case of endometrial cancer or CX 
24 in case of cervical cancer. Exclusion criteria was the 
inability to understand the questionnaire. There was no 
limitation with regard to age or performance status. We 
analyzed overall health and overall quality of life, bladder 
symptoms, disuria and bladder and faecal incontinence. We 
also analyzed items related to sexual function (sexual 
interest and activity) and sexual symptoms (vaginal dryness).  
Results: Everybody accepted to compile the questionnaire 
and only 5 patients needed some assistance. Most patients 
found that the questions were clear and easy to understand. 
Median age was 62.3 years (range 29–81). With a median 
follow up of 4.5 years (range 1.2-6.5), 78% of women were 
free of disease and 21% had evidence of tumour progression 
or relapse. All items exhibited good compliance with no 
missing values except those regarding sexual function that 
were missed in 37.5% of patients. The 92.5% of women 
judged their overall health and QoL good. In particular all 
patients with no evidence of tumour relapse judged a 
favorable QoL, and only 36% of patients with progression 
disease judged their QoL poor.  
Table 1 shows the answers considering tumour type and 
treatment modality. 
We calculated the Chi-Square Test to compare treatment 
modalities (operated or non-operated patients; pelvic 
external beam radiotherapy ± brachytherapy) and tumour 
sites (cervical or endometrial) for the various items. For all 
the items of Table 1, we did find a trend just below the 
threshold of significance (p=0.06-0.08). 
 
 
 
Conclusions: From our analysis, it emerged a good QoL for 
the whole series with similar percentages for the different 
tumour types and treatment modalities. The presence of 
tumour progression reduced QoL. We found that patients 
treated for cervical cancer complained of higher incidence of 
disuria and bladder incontinence. No patient complained of 
severe symptoms related to gastro-intestinal dysfunction or 
faecal incontinence.  
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